SCHEMBL381470

SCHEMBL381470

O=C(O)CCN1CCN(c2ccc(OCc3ccc(C(F)(F)F)cc3)cc2)CC1.[LiH]

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.59
HRH3 Q9Y5N1 1/20 0.55
PPARD Q03181 1/20 0.54
PPARA Q07869 1/20 0.54
MAPT P10636 1/20 0.54
RAB9A P51151 1/20 0.54
KCNH2 Q12809 1/20 0.52
MCHR1 Q99705 1/20 0.52
SLC6A5 Q9Y345 6/20 0.51
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
MAOB P27338 2/20 0.49
CACNA1G O43497 1/20 0.48
HTR1A P08908 1/20 0.48
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
ME2 P23368 1/20 0.47
ME1 P48163 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12041675 0.99 FFAR1 (0.60) FFAR1HRH3PPARDPPARAMAPT
Lithium Ion SCHEMBL9983979 0.88 FFAR1 (0.54) FFAR1HRH3PPARDPPARAMAPT
SCHEMBL12041677 0.87 FFAR1 (0.55) FFAR1HRH3PPARDPPARAMAPT
SCHEMBL457489 0.87 DRD2 (0.56) PPARDPPARACA1CA2CA7
SCHEMBL381104 0.86 RAB9A (0.70) FFAR1MAPTRAB9AHTR1A
SCHEMBL12041888 0.86 DRD2 (0.57) PPARDPPARACA1CA2CA7
SCHEMBL12041572 0.85 RAB9A (0.71) FFAR1MAPTRAB9AHTR1A
SCHEMBL15442411 0.82 HRH3 (0.62) FFAR1HRH3MAPTRAB9AKCNH2
SCHEMBL12060047 0.81 SLC6A5 (0.51) FFAR1HRH3PPARDPPARAMAPT
SCHEMBL15761275 0.81 SLC6A4 (0.52) FFAR1PPARDPPARAKCNH2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
EP-2408742-A1 ANTHELMINTIC AGENTS AND THEIR USE Intervet International B.V. (NL) 2012-01-25 EP disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO FFAR1 4754/4885HRH3 311/4885PPARD 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.